IL6 and type 1 diabetes mellitus: This study demonstrates that T1D DR PBMCs show proinflammatory phenotypes that are consistent with enhanced innate responses, specifically enhanced PBMC-released IL-10, IL-6 and in particular IL-17A production from myeloid cells, and impaired adaptive responses, specifically impaired CD3 T cell IFN-γ production.